Veracyte (VCYT) has seen impressive growth over the past year, with its shares jumping 44%. It has significantly outperformed the industry’s 3.9% rise and the S&P 500 composite’s 24.4% gain.With a Zacks Rank #1 (Strong Buy) at present, the global diagnostics company is gaining more market shares from the strength of the Afirma solution. Veracyte is also making strides with the Decipher Prostrate test and advancing its long-term growth drivers, which are highly encouraging. Headquartered in San Francisco, CA ...

Veracyte (VCYT) delivered third-quarter 2024 earnings of 19 cents per share, which marked a stupendous improvement from the year-ago period’s loss of 3 cents per share. The figure beat the Zacks Consensus Estimate of 2 cents per share by a huge 850%.The company-adjusted earnings per share (EPS) were 33 cents, reflecting a 94.1% year-over-year improvement.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.RevenuesRevenues increased 28.6% year over year to $115.9 million, which outpaced ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36156 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 20-5455398 (State or ...

Veracyte, Inc. (NASDAQ:VCYT) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Shayla Gorman - Senior Director, Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Conference Call Participants Subbu Nambi - Guggenheim Securities Andrew Brackmann - William Blair Lu Li - UBS Tejas Savant - Morgan Stanley Sung Ji Nam - Scotiabank Thomas DeBourcy - Nephron Research Mike Matson - Needham Puneet Souda - Leerink Partners Operator Good ...

Veracyte (VCYT) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 850%. A quarter ago, it was expected that this molecular diagnostic company would post a loss of $0.03 per share when it actually produced earnings of $0.30, delivering a surprise of 1,100%.Over the last four quarters, the co ...

Exhibit 99.1 Veracyte Announces Third Quarter 2024 Financial Results Grew total revenue to $115.9 million, an increase of 29% Grew testing revenue to $109.5 million, an increase of 34% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., November 6, 2024 --- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2024. "The strong momentum across our testing business continued during the third quarter as we delivered record revenue ...

Veracyte's (VCYT) progress with the three long-term growth drivers exhibits robust growth potential for the upcoming quarters. The record volume growth of the Decipher Prostrate test instills optimism, supported by the distinct recognition from the NCCN (National Comprehensive Cancer Network). The Afirma GRID offering can help the company extend its reach into the endocrinology market. Meanwhile, declining biopharma revenues and macroeconomic issues are worries for Veracyte. In the past year, this Zacks Ran ...

A month has gone by since the last earnings report for Veracyte (VCYT) . Shares have added about 9.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Veracyte due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Veracyte's Q2 Earnings Top Estimates,'24 Sales View Up Ver ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? Developed alo ...

After reaching an important support level, Veracyte, Inc. (VCYT) could be a good stock pick from a technical perspective. VCYT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average. There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving ...